Efficacy News and Research

RSS
DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Envoy expands drug discovery collaboration with The Scripps Research Institute

Envoy expands drug discovery collaboration with The Scripps Research Institute

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

NMT releases new device for treatment of post-operative nausea

NMT releases new device for treatment of post-operative nausea

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

Experts at Ninth International Symposium discuss health effects and safety of S-equol

Experts at Ninth International Symposium discuss health effects and safety of S-equol

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.